MYL12B

Across TCGA pan-cancer cohorts, MYL12B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MYL12B data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MYL12B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYL12B expression acts as an unfavorable survival marker.

BLCA are the cancer types where MYL12B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.212	0.720	.010	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MYL12B–BLCA (OS)

Open the BLCA breakdown →